With over 13 million confirmed COVID-19 cases and fatality count closing the mark of 600,000 worldwide, the race to the finishing line of finding cure to the vile Coronavirus continues to step forward day-after-day, and week-after-week.
Globally, at least 166 Vaccine candidates are undergoing some pre-clinical or clinical stage of vaccine trials.
According to the Coronavirus Vaccine Tracker of New York Times, 135 vaccines are undergoing the preclinical stage, with Phase-I, II, and III vaccine trials counting to 15, 11, and 4 vaccine candidates respectively.
One vaccine candidate from a German Biotech firm, BioNtech claims that after successful clinical trials it is awaiting the regulatory approval of its vaccine candidate for a wider public use, that it expects to obtain by the end of this year, Wall Street Journal reports.
A look at some highly anticipated vaccine candidates worldwide:
Moderna Vaccine: Moderna was one of the first companies in the world that put its vaccine candidate into human trials. It has published “promising” Phase-I results, with its Phase-II result published on July 14.
The Phase-III trials are scheduled to begin by July 27, and the company has projected to make vaccine doses ready by early 2021.
BioNTech-Pfizer Vaccine candidate: Berlin-based BioNTech-led vaccine candidate so-far remains the only vaccine candidate that has its feet in the Approval stage already.
In collaboration with New York-based Pfizer, the company has produced results for its Phase-I and Phase-II trials, although with volunteers experiencing moderate side effects like sleep disturbances and sore joints.
But since its volunteer-size in Phase-I and II was greater than other and was considered ‘significant’ by the authorities, it has already started making efforts for an approval with a Fast-track status it has received from the US FDA due to which company hopes to complete the approval by the end of this year, with a parallel completion of its Phase-III trial as well.
Company expects to make over a billion doses by December, ready for human use.
Astrazeneca-Oxford Vaccine: Based on chimpanzee adenovirus called ChAdOx1, the vaccine candidate is currently in Phase-II trials in England, and Phase-III trials in South Africa and Brazil.
With a total manufacturing capacity estimated at 2 Billion doses per year by the company (In partnership with Pune-based Serum Institute of India), the British media citing its sources has claimed a ‘good news’ on vaccine development front from Astrazeneca’s end.
Zydus Cadila vaccine: Ahmedabad-based vaccine maker is the second only Indian pharmaceutical firm to enter vaccine race after Hyderabad-based Bharat Biotech.
Its pre-clinical trials have generated ‘successful’ results, and the company has started Phase-I, and Phase-II human trials.
Bharat Biotech’s Covaxine: Hyderbad-based Bharat Biotech’s Covaxine, in collaboration with Pune-based National Institute for Virology, and Indian Council of Medical Research, started its human trials in volunteers at AIIMS-Patna.
The ICMR’s 15th August target for the completion up to Approval process has been received with skepticism, but the pre-clinical results have generated ‘promising results’.
NovoVax vaccine: The Maryland-based vaccine candidate is the only one of its kind that has received $1.6 Billion in its federal funding.
The company projects to deliver the vaccine by the first quarter of 2021, with Phase-III results having already begun by its end.
Sinopharm Vaccine: State-owned Chinese company Sinopharm is the second-only Vaccine maker after Germany’s BioNTech, which is fast moving towards Approval stage of vaccine development.
Around 15,000 volunteers are undergoing its vaccine trial, and the company, quite ambitiously, has set the target of producing billions of vaccine doses before the end of the year.
Content created and supplied by: Faithy_Media (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More